

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 9, 2020

**Ekso Bionics Holdings, Inc.**

(Exact Name of Registrant as specified in its charter)

**Nevada**  
(State or Other Jurisdiction  
of Incorporation)

**001-37854**  
(Commission File Number)

**99-0367049**  
(IRS Employer  
Identification No.)

**1414 Harbour Way South, Suite 1201**  
**Richmond, California 94804**  
(Address of principal executive offices, including zip code)

**(510) 984-1761**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	EKSO	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02            Results of Operations and Financial Condition**

On April 9, 2020, Ekso Bionics Holdings, Inc. (the “Company”) reported certain preliminary financial results for the quarter ended March 31, 2020, and also provided an update on the impact of the COVID-19 pandemic to the Company’s business activities and operations. In addition, the Company reported that as of April 7, 2020, it had regained compliance with the minimum bid price requirement required by the listing rules of The Nasdaq Capital Market. The full text of the press release announcing such information is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01            Financial Statements and Exhibits**

(d)       Exhibits

<u>Exhibit</u>	<u>Description</u>
<u>99.1</u>	<u><a href="#">Press Release dated April 9, 2020</a></u>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EKSO BIONICS HOLDINGS, INC.

By: /s/ John F. Glenn

Name: John F. Glenn

Title: Chief Financial Officer

Dated: April 9, 2020

---



## **Ekso Bionics Provides COVID-19 Business Update and Reports Preliminary First Quarter 2020 Financial Results**

### *- Company Regains Nasdaq Listing Compliance -*

**RICHMOND, CA – April 9, 2020** – Ekso Bionics Holdings, Inc. (Nasdaq: EKSQ), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary financial results for the first quarter ended March 31, 2020 and provided an update on the impact of the COVID-19 pandemic on its business activities. In addition, the Company confirmed that as of April 7, 2020, it has regained compliance with the minimum bid price requirement required by the listing rules of the Nasdaq Capital Market.

The COVID-19 pandemic impacted Ekso Bionics' business in the first quarter as its customers shifted their priorities to prepare for and manage their business during the pandemic. This has caused many of its customers to delay orders, which are typically booked in the last few weeks of a quarter. It is important to note that a majority of the Company's customers have indicated that their originally planned orders are delayed and not canceled, pending the return to a more normal environment.

Total revenue for the first quarter of 2020 is estimated to be in the range of \$1.4 - \$1.5 million. Cash at March 31, 2020 is estimated at \$8.5 million, compared to \$10.9 million at December 31, 2019.

Ekso Bionics is taking several steps to adjust its business to the current circumstances. To reduce expenses and adjust operations to match customer needs, the Company has furloughed a portion of its workforce. The Company is also in the process of applying for the loans under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (CARES Act) administered by the U.S. Small Business Administration, as well as a similar program in Germany.

Ekso Bionics has also adapted its support, training, and service models to ensure all of its customers can continue their Ekso programs without interruption and without Ekso Bionics personnel being present at customers' facilities. These revised work models also allow the Company to engage with prospective customers to ensure that it can support new business as customers businesses return to normal.

"The COVID-19 pandemic has impacted our customers' businesses, and subsequently, our business as customers delay longer-term technology decisions. As a result, we have shifted our business operations to reduce expenses and align our strategy with current market conditions," said Jack Peurach, President and Chief Executive Officer of Ekso Bionics. "As a company committed to meeting the needs of our customers, we are evolving our business so we can continue to support our customers while they focus their energy on protecting their patients and staff from COVID-19. We also took the difficult decision to furlough a portion of our dedicated and valued employees in order to weather this extraordinary global health crisis, bring expenses more in-line with business operations over the short-term, and allow us to resume normal activities when our customers are ready."

The anticipated results discussed in this press release are based on management's preliminary, unaudited analysis of financial results for the period ended March 31, 2020. As of the date of this press release, the Company has not completed its financial statement reporting process for the period ended March 31, 2020, and the Company's independent registered accounting firm has not audited the preliminary financial data discussed in this press release. During the Company's quarter-end closing procedures and review process, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary operating results. The Company expects to report complete first quarter 2020 financial results after the markets close on Thursday, April 30, 2020.

**About Ekso Bionics®**

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSQ. For more information, visit: [www.eksobionics.com](http://www.eksobionics.com) or follow @EksoBionics on Twitter.

**Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the Company's preliminary financial results, future customer orders and the impacts of the Company's strategies to address changing conditions in light of COVID-19. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current plans, objectives, beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company's finalization of its financial statements for and as of the quarter ended March 31, 2020, information or new changes in facts or circumstances that may occur prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 that are required to be included in such annual report, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing organization or partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, the Company's failure to implement the Company's business plans or strategies, the COVID-19 pandemic and global economic conditions. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit the Company's website at [www.eksobionics.com](http://www.eksobionics.com) or refer to our Twitter page at @EksoBionics. The Company does not undertake to update these forward-looking statements.

**Media Contact:**

Carrie Yamond Mas  
917-371-2320  
[cmass@eksobionics.com](mailto:cmass@eksobionics.com)

**Investor Contact:**

David Carey  
212-867-1768  
[investors@eksobionics.com](mailto:investors@eksobionics.com)

---